Viropro completes feasibility study for BioChallenge as part of agreement

By Lisa Kerner

Charlotte, N.C., Aug. 21 - Viropro Inc. completed a feasibility study for Biochallenge SA as part of the companies' previously announced binding memorandum of understanding to jointly develop and produce several therapeutic proteins.

The agreement is expected to generate revenues of $27 million over 12 to 14 years for Viropro.

Viropro is a Montreal-based biopharmaceutical company that operates mainly through its subsidiary Viropro International Inc.

BioChallenge is a privately held pharmaceutical company based in Tunisia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.